About Mereo BioPharma
Mereo BioPharma is a company based in Redwood City (United States) founded in 2004 was acquired by Mereo BioPharma in December 2018. It operates as a HealthTech. Mereo BioPharma has raised $116.98 million across 6 funding rounds from investors including Mereo BioPharma, Celgene and Adams Street Partners. Mereo BioPharma offers products and services including Setrusumab, Alvelestat, Etigilimab, Navicixizumab, and Leflutrozole. Mereo BioPharma operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Redwood City, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Mereo Biopharma Group Plc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$116.98 M (USD)
in 6 rounds
-
Latest Funding Round
$22.25 M (USD), Post-IPO
Dec 06, 2013
-
Investors
Mereo BioPharma
& 9 more
-
Employee Count
Employee Count
-
Acquired by
Mereo BioPharma
(Dec 05, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Mereo BioPharma
Mereo BioPharma offers a comprehensive portfolio of products and services, including Setrusumab, Alvelestat, Etigilimab, Navicixizumab, and Leflutrozole. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Developed for osteogenesis imperfecta in pediatric patients.
Designed for treatment of rare respiratory diseases.
Created for potential oncology and rare disease applications.
Formulated for advanced solid tumors and oncology.
Developed for rare endocrine and metabolic disorders.
Targeted for treatment of acute inflammatory conditions.
Funding Insights of Mereo BioPharma
Mereo BioPharma has successfully raised a total of $116.98M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $22.25 million completed in December 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Post-IPO — $22.2M
-
First Round
First Round
(07 Sep 2005)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2013 | Amount | Post-IPO - Mereo BioPharma | Valuation |
investors |
|
| Dec, 2013 | Amount | Post-IPO - Mereo BioPharma | Valuation |
investors |
|
| Nov, 2010 | Amount | Grant - Mereo BioPharma | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Mereo BioPharma
Mereo BioPharma has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Mereo BioPharma, Celgene and Adams Street Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private markets investment management with strategies in equity, credit, and secondary investments.
|
Founded Year | Domain | Location | |
|
Early-stage healthcare startups are supported with venture capital.
|
Founded Year | Domain | Location | |
|
Venture capital and private equity investment firm
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Mereo BioPharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Mereo BioPharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Mereo Biopharma Comparisons
Competitors of Mereo BioPharma
Mereo BioPharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Mereo Biopharma
Frequently Asked Questions about Mereo BioPharma
When was Mereo BioPharma founded?
Mereo BioPharma was founded in 2004 and raised its 1st funding round 1 year after it was founded.
Where is Mereo BioPharma located?
Mereo BioPharma is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Is Mereo BioPharma a funded company?
Mereo BioPharma is a funded company, having raised a total of $116.98M across 6 funding rounds to date. The company's 1st funding round was a Grant of $1.2M, raised on Sep 07, 2005.
What does Mereo BioPharma do?
Mereo BioPharma Group plc is engaged in the development of innovative therapies for rare diseases. The company operates in the biopharmaceutical sector, identifying and advancing treatments with significant unrealized potential. Solutions such as Setrusumab for osteogenesis imperfecta and Alvelestat for respiratory conditions are developed through clinical-stage research. Collaboration with partners, patient communities, and healthcare professionals is emphasized to enhance therapeutic outcomes. The focus remains on addressing unmet medical needs in niche markets with specialized drug development.
Who are the top competitors of Mereo BioPharma?
Mereo BioPharma's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Mereo BioPharma offer?
Mereo BioPharma offers Setrusumab, Alvelestat, Etigilimab, Navicixizumab, and 2 more products and services.
Who are Mereo BioPharma's investors?
Mereo BioPharma has 10 investors. Key investors include Mereo BioPharma, Celgene, Adams Street Partners, Latterell Venture Partners, and Morgenthaler.